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Thesis Abstract
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OBJECTIVES:
1. To assess the level of insight and attitude towards medication in patients with chronic
Schizophrenia.
2. To determine factors associated with insight and attitude to medication in patients with
chronic schizophrenia.
3. To determine the relationship between insight and attitude to medication in this group of
patients with chronic schizophrenia.
METHODS:
A cross-sectional survey of insight into the illness and attitude towards medication of consenting
patients suffering from chronic schizophrenia using the schedule for assessment of insight (SAI-
E) and drug attitude inventory (DAI). Clinical assessment of psychopathology using PANSS and
assessment of treatment adherence using subjective (Morisky Scale) and objective (chart review)
were done to supplement assessment of relation between severity of illness, insight, attitude
towards medications and compliance to medications  in consecutively recruited outpatients. Data
was analyzed using chi square statistics for significant association with a corresponding p value
of less than 0.05 suggesting statistically significant association between the variables.
RESULTS:
All the 101 patients suffering from chronic schizophrenia were found to be mild to moderately
ill in terms of psychopathology and had good to moderate insight into their illness. Those who
had good insight into their illness expectedly had a favorable attitude towards medications.  The
degree of psychopathology was inversely correlated with insight into the illness and compliance
to medications. Compliance to medications is a larger complex construct which seems to be
affected by the severity of illness; however neither good insight into the illness nor a favorable
attitude towards medications seems to significantly alter the rates of compliance to treatment.
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INSIGHT AND ATTITUDE TO MEDICATION IN SCHIZOPHRENIA 
INTRODUCTION  
Schizophrenia, with an approximate lifetime risk of 1 in 100, and an annual incidence of 
0.5 to 5.0 per 10,000, is one of the leading causes of disability in the world. As per the 
assessment of leading cause of years lived with disability, worldwide statistics showed 
that schizophrenia ranks ninth in the order among various other disorders that causes 
disability to an individual. (WHO, 2005) 
The onset of schizophrenia is usually in early adulthood. Schizophrenia has an earlier 
onset in males. The mean ages of onset are 20 and 25 years in males and females 
respectively (Easton and Chen, 2006) . The course is varied depending upon multiple 
factors including patient characteristics, severity of illness, availability of treatment, 
response and adherence to medications, and the availability of rehabilitation services. 
Irrespective of the course, the illness is marked by impairment and disability in socio 
occupational functioning, the extent of which is influenced by presence of residual 
psychotic symptoms. The early onset and chronic course adversely affect interpersonal, 
familial, occupational, financial and social domains. The stigma associated with the 
disorder further delays the identification, diagnosis and treatment. In addition, 
schizophrenia predisposes the affected to medical co morbidities, resulting in poorer 
outcomes. Only about half of all patients with schizophrenia receive treatment. It has been 
shown that early intervention can improve the outcome of treatment and that long duration 
of untreated psychosis can lead to poor treatment response(Kane, 2006) . 
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Treatment of Schizophrenia 
The treatment of schizophrenia can be divided into pharmacological and non-
pharmacological.  
 
The non-pharmacological treatment methods include psychotherapy; cognitive behavior 
therapy, family therapy and electroconvulsive therapy (Sadock & Sadock, 2007) 
Pharmacological treatment involves mainly treatment with antipsychotic group of 
medication.  Since the introduction of Chlorpromazine in the 1950s a number of 
antipsychotics have been marketed. They are broadly divided into first generation and 
second-generation antipsychotics. Introduction of this group of medication has changed 
the outcome of this disorder in many patients. In spite of the availability of large number 
of medications the deciding factor for a successful treatment will be patient’s compliance 
with treatment. However treatment adherence and remission of the active phase of the 
disorder are not achieved in a large group of patients with schizophrenia.  
 
When individuals with schizophrenia do not perceive themselves as ill, they are less likely 
to seek or remain in treatment. Such patients may not appreciate the benefits of treatment 
fully, and may put themselves at higher risk of discontinuing treatments. This in turn may 
increase the risk of relapse.  Poor insight into illness and a not favourable attitude toward 
medications may thus be important determinants of clinical and occupational outcome and 
may offer useful avenues for intervention by the treatment team.  
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The study on the patient’s insight and attitude to medication will help health care 
professionals in understanding the patients’ problem; their concerns and appropriate steps 
can be taken to overcome the problem of non-compliance. Patients may tend to 
discontinue treatment when they become asymptomatic. Another reason for poor 
compliance may be the stigma associated with mental illness. Patients’ attitude to 
medication and compliance also matter towards treatment.    
 
The present study is an attempt at learning more about the  interaction between the four 
variables of insight, psychopathology, attitude to medication and adherence in patients 
with schizophrenia.  The psychopathology, insight about the disorder and  attitude 
towards treatment in   general and medication in particular are all inter linked and may 
influence the treatment adherence and outcome.The study is planned in a hospital-based 
sample, on out patients with a diagnosis of schizophrenia, which was made using 
International Classification of Diseases and related health problems, tenth revision 
criteria.  
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REVIEW OF LITERATURE  
Schizophrenia 
Schizophrenia is a major psychiatric disorder which is complex in nature, with multiple 
groups of symptoms. These symptoms are usually grouped into three under positive, 
negative and cognitive symptoms. It affects different areas of patient’s life, leading to 
marked impairment on individual’s functioning in the society. The impact of this disorder 
on the patient, his or her family, work and social life is huge. Treatment of schizophrenia 
thus becomes extremely important. Outcome in Schizophrenia can be viewed not only as 
improvement in psychopathology but also as improvement in the various domains of 
patient’s life including community functioning and self-satisfaction.   
However treatment of schizophrenia is made difficult by different factors. These include 
factors   related to the disorder, the patient, the treatment modalities, the therapist, the 
family or the social milieu.  When we consider the first two, namely factors related to the 
disorder and the patient, psychopathology, insight, attitude of the patient to treatment and 
compliance of the patient to treatment can be seen as important components.  Poor insight 
and denial of illness are common in patients with schizophrenia . They are widely 
believed to affect the treatment adversely. How the different components like 
psychopathology, insight, attitude to medication and treatment compliance interact with 
one another becomes important in the management of this major mental illness which has 
a prevalence of 1% worldwide.  
In the CATIE study  (Lieberman et al., 2005) though no difference was found between the 
effectiveness of the two groups of antipsychotics, namely first generation and second 
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generation, it was found that compliance with medication is a major problem. Seventy-
four percent of patients discontinued the study medication before 18 months. It	  has	  been	  
shown	  that	  even brief periods of partial non-adherence lead to greater risk of relapse than 
what is commonly assumed (Masand et al., 2009) . Compliance with medication thus 
becomes a crucial variable in the prognosis of schizophrenia. 
Poor adherence to medication is a well-known phenomenon in clinical practice . This is 
applicable to all medical specialties. And adherence is not an all or none issue either. Most 
patients may be partially adherent. 	  
Notably, treatment adherence is considered to have a major influence on achieving 
clinical remission (San et al., 2007).	  
Moreover, patients who fail to take their medication as prescribed are at an increased risk 
of relapse (Masand and Narasimhan, 2006).   
A review    of articles by Masand et al., (2009)  published between the years 1980 and 
2008 about adherence by , compliance and Schizophrenia reveals that failure to adhere to 
medication as prescribed can have a major impact on the course of illness and treatment 
outcomes. Even relatively short gaps in medication coverage increase the risk of relapse. 
Problems with adherence are common early in the course of illness, when the impact  of 
relapse can be particularly devastating. They conclude that clinicians in primary care and 
psychiatric settings need to be vigilant for signs of adherence problems among their 
patients. They should be ready to act when necessary to prevent or reduce the 
consequences of inadequate medication cover. Relapse prevention strategies, particularly 
for patients with early psychosis, should include ensuring that medication is taken 
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regularly.  The impact of psychotic relapse on the course of illness is huge and  relapse 
prevention strategies should encourage greater awareness of the consequences  of partial 
adherence and should incorporate the necessary  steps to minimize or eliminate the 
problem, especially  during the early stages of the illness (Masand et al., 2009). 
With regard to schizophrenia, there have been advances related to treatment options over 
the past few years. In spite of this, schizophrenia continues to be one of the most disabling 
diseases in psychiatry. Treatment of schizophrenia is made complex by the different 
issues that need to be considered with regard to the choice of medication. Medication has 
to be chosen keeping in mind the past history of drug response, the psychopathology, co 
morbidities, and the side effect profile. In addition to these, the patients preference and 
long term objectives  also need to be considered. A lot more needs to be known with 
regard to the development  of the illness, to help therapists deliver personalized treatment 
(Kane, 2006) 
 
Insight 
 Assessment in clinical psychiatry terms insight as “ patients’ capacity to understand the 
nature, significance and severity of his or her illness” (Sims A, 2009) Such an insight  has 
major  implications for phenomenology, clinical management, coping, help seeking and  
compliance towards treatment. 
 
Sadock & Sadock (2007) defines insight as a patient’s degree of awareness and 
understanding about being ill. They may show  complete denial of their illness or may 
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show some awareness that they are ill but may place the blame on others, on outside 
factors  or even on physical  factors.   
 Sadock & Sadock( 2007) divide insight in to six levels.  
1. Total denial of illness.  
2. Some awareness of sickness, however denying it at the same time.  
3.  Aware that they are sick but attributing it to factors out side their mind.  
4. Aware that illness is due to something unknown in themselves.  
5. Admission that they are ill and that it is due to their own psychological factors ; 
however they are not able to apply this awareness to master the situation or for 
future experiences. Not able to effect an adaptive change in their behaviour. This 
is termed intellectual insight.  
6. Emotional insight which is described as the awareness of one’s own emotions and 
motives  and the important people behind one’s behaviour; this leading to basic 
changes in behaviour.  
 
Impaired insight is the reduced ability to understand the reality of the situation. Patients 
with schizophrenia are said to have poor insight in to the nature and the severity of their 
illness. And this poor insight may cause poor treatment adherence. Insight involves  
various aspects like awareness of symptoms, difficulty in getting along with others and 
the reasons for these problems (Sadock and Sadock, 2007) 
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Patients with schizophrenia showed limited awareness about their illness, even though 
they were aware of their deficits. It has been suggested that treatment may have to be 
targeted at specific realms of insight (Arango and Amador, 2010). 
 
The concept of insight has undergone considerable changes during the past 100 years. 
Initially insight was defined as a single dimension of  awareness of having a disorder.  It 
was   applied as if the patient either possessed insight or lacked it completely.   Later 
writers developed insight into a multidimensional and continuous construct(Mintz et al., 
2003) The different dimensions of awareness, attribution and action now evaluate 
patients. First dimension includesthe extent of the awareness about illness, its signs and 
symptoms, and the need for treatment.  The degree to which they attribute the benefits to 
treatment, accept the illness label and understand the social consequences of illness are 
also included in insight (Amador and Kronengold, 2004).  
 
Literature has categorized patients with schizophrenia in to three groups: those with full 
insight (aware correct attributers) are the first group. The second group are those aware of 
being unwell, but who misattributed their symptoms (aware, incorrect attributers). The 
third group comprises of those who are unaware of being ill (unaware)(Mysore et al., 
2007). Studies have documented the inverse relationship between psychopathology and 
insight(Saravanan et al., 2007),(Amador, X. F and David, A. S., 1998).(Saravanan et al., 
2010),(Drake et al., 2007)  
 
	   9	  
Arango wonders whether impairment in insight is a cognitive deficit, anasognosia. Those 
patients with anosognosia were completelyunaware of the deficits. And most studies of 
nonadherence and partial adherence totreatment find that the best predictor is unawareness 
of illness or poor insight.Problems with illnessawareness are associated with 
neuropsychological deficitsand are predictive of poor treatment compliance and poorer 
outcomes. There are suggestions to include this dimension of illness awareness in future 
diagnostic systems, as a specifier for schizophrenia(Arango and Amador, 2010). 
 
Among factors influencing insight are baseline intelligence, duration of untreated 
psychosis and personality traits(Parellada et al., 2009).  
Insight among patients with Schizophrenia is found to be associated with the emotional 
responses of the relatives and their insight into the illness(Brent et al., 2011).  
 
There have been recent findings arguing for an evolving rather than a static concept of 
insight; that insight and illness perspectives are coping mechanisms secondary to 
psychopathology and course of the illness(Johnson et al., 2012).  
In a study by Shankar  et al(2006) done among patients from a South Indian population, 
on the insight of patients with psychotic disorders, it was reported that  about 25.3% were 
aware of illness, 21%  were moderately aware and about 43.3% were unaware of 
illness(Explanatory model of illness among patients with chronic mental disorders 
attending traditional healers, 1998). Poor insight in psychosis is due to a lack of awareness 
of having an illness and its deficits, its consequences and awareness that he/ she needs 
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treatment for their deficit. Poor insight and denial of illness are prevalent features of 
schizophrenia that is widely believed to have adverse clinical effects.  
Among those suffering from schizophrenia, about 50% fail to recognize their disease or 
the necessity for medication. Many causative models and treatment strategies have been 
discussed for deficiency of insight. Treatment strategies are mainly focused on  helping 
patients cope with the disease(Baier, 2010). 
 
Metacognition and insight 
There are different theories regarding the origins of poor insight in schizophrenia. One 
such theory suggest that it may result, in part, from deficits in metacognitive capacity.  
The ability to think about thinking, both one's own and the thinking of others, is termed 
metacognitive capacity. This has been studied and it is found that in persons with 
Schizophrenia the lack of metacognition may be linked to insight independent of 
concurrent other impairments in neurocognition from Indianapolis(Lysaker et al., 2011). 
An important extension of the insight concept was introduced with the description of 
‘‘cognitive insight’’. It is defined as a patient’s current capacity to evaluate his or her 
abnormal and atypical experiencesand  interpretations of events.  In contrast to patients 
with nonpsychotic disorders (eg, depression or panic disorder), patients with psychosis are 
severely limited in their capacity to evaluate their problems, to recognize the cognitive 
errors and correct them. 
Taking a cognitive view on insight, one can describe patients to have impairment in the 
ability to be objective about their psychotic experience, with a decreased capacity to put 
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them in perspective, with resistance to receiving corrective information from others and 
increased confidence in their judgements (Beck et al., 2011).  
 The Beck Cognitive Insight Scale (BCIS) measures patients’ capacity for distancing 
themselves from and re-evaluating abnormal beliefs and misinterpretations  (Beck et al., 
2004) 
 
The assessment of insight  
The assessment of ‘‘clinical insight’’ has become invaluable for the formulation and 
treatment of psychosis. There are various tools available to measure insight. One such is 
the SAI-E. 
 
Schedule for Assessment of Insight: Expanded Version (SAI-E) 
The expanded version of the Schedule for Assessment of Insight has been applied widely 
in Western and nonWestern countries for the assessment of insight. It comprises questions 
to assess three dimensions of insight: awareness, relabelling of symptoms and adherence 
to treatment, plus labelling a hypothetical contradiction item added to evaluate the 
person’s capacity to consider other’s perspective. Each dimension comprises two or three 
questions which are scored on a 3 point scale from 0 (no insight) to 2(good insight).  The 
supplementary question is scored from 0-4 and this is added to the total score. This 
expanded version also includes items on awareness of change, difficulties resulting from 
the psychiatric condition and insight into key symptoms(Kemp, R. and David, A., 1997) 
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Insight and Depression 
The relationship between insight and depression has also been studied.  Does depression 
result from good insight? Depression with its risk of suicide, if related to good insight, 
may in turn contribute to suicide risk.  The improvement in insight positively correlates 
with level of dysphoria. Hence, poor insight may protect against depression in the early 
stages of recovery from Schizophrenia. Depression has been  found to be associated with 
lower levels of insight in contradiction to previous findings(Arango and Amador, 2010). 
 
Insight and Psychopathology 
Many of the earlier studies conclude that insight and psychopathology have an inverse 
relationship(Saravanan et al., 2007)(Amador, X. F and David, A. S., 1998) 
 
This is supported by western and non-western studies. For example in the  study done by 
Sulekha et al, (2009) in Vellore, the analysis brought out significant inverse correlation 
between insight and psychopathology. The direction of relationship between insight and 
psychopahtology has also been studied(Sulekha VK, 2009). That better insight lowered 
psychopathology has been supported by a four-week longitudnal study on insight and 
psychopathology by Mehrotra et al (Mehrotra and Sengupta, 2006) The reverse direction 
of the relationship between insight and psychopathology has been supported by the study 
done in Vellore, by Johnson et al., (2012) 
 who argued that many of the studies that conclude the contrary fail to account for the 
illness characteristics that influence outcome(Johnson et al., 2012a). Their data suggested 
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that psychopathology and illness characteristics predict insight, explanatory models and 
outcome in schizophrenia. They further argue that insight maybe secondary to 
pyschopathology. They describe insight as a coping mechanism rather than being causally 
related to the outcome.  
Studies that assess the relationship of insight with psychopathology and neurocognition 
find that  insight is  partly explained by them. This may be just a reflection of the 
complexity of the phenomenon of psychosis(Arango and Amador, 2010). 
  
Personality traits and insight  
What is the relationship between insight and personality? Studies have been done in this 
area as well.  In one of the recent publication it has been shown that Premorbid 
personality traits may help to identify patients who are at high risk for having lack of 
insight  (Campos et al., 2011). 
 
Insight and course of schizophrenia 
The presence of insight is known to prevent relapse of the psychotic symptoms as 
evidenced by a study done in Vellore (SobhaLakshmi B, 2006)  
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Attitude to medication in patients with schizophrenia 
Attitude refers to the patient’s perception towards different aspects of medications 
including medication intake, medication effects and/ or medication side effects.  
 The development of effective antipsychotic drugs and the changes in the attitude towards 
medication have changed the pattern of hospitalizations for patients with Schizophrenia 
(Sadock & Sadock, 2007) The attitude of the patient towards treatment with 
antipsychotics determines the compliance towards medication. 
The predictors of attitude towards treatment  include patient’s response to the 
antipsychotic medication,  side effects of medicines, illness duration, insight, patients’ 
relationship with staff and patients perception about admission as reported by studies done 
independently by Day et al., (2004) and Hofer et al., (2005).  
An association between positive attitudes towards medication, level of psychopathology, 
functioning and medication compliance is found, independent of insight.  
Educational interventions that affect these attitudes may be an important part of 
psychosocial rehabilitation and/or recovery-oriented services. There is a need for a study 
that will measure the relationship between insight and attitude to medication in the Indian 
context. 
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A mediational model describes best the relationship between insight and attitude 
towards medication. 
Awareness of illness contributed to medication adherence via patients' perceived necessity 
of antipsychotics. The model reveals a direct negative relationship between concerns 
regarding antipsychotics and adherence and an indirect negative effect of a general 
distrust regarding pharmacotherapy and adherence via antipsychotic specific 
attitudes.interventions to enhance medication adherence may be more effective if they 
focus on treatment related attitudes rather than on global insight into illness. Clinicians 
may not only enhance the patients' perceived necessity of antipsychotic treatment but also 
explore and address concerns and the patients' distrust in pharmacotherapy in a more 
personalized way. 
The Health Belief Model states that medication adherence is primarily determined by 
beliefs i.e., perceptions of adherence costs and benefits, susceptibility, and outcome 
severity. Study done among patients in the early episode of schizophrenia support this and 
emphasise the role of attitudes toward medication as a predictor of adherence(Baloush-
Kleinman et al., 2011).  
 
Measurement of attitude to medication 
Presence or the absence of Insight and an unfavourable attitude towards medication are 
the two significant variables  that have repeatedly been shown to be risk factors for non 
adherence (Yang et al., 2012).  
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Drug attitude inventory (DAI-30) is a tool to predict poor adherence in first-episode 
schizophrenia. A study compared the short version (DAI-10) with DAI-30 in long-term 
schizophrenia.  They conclude that DAI is a useful self-report instrument to  assess a 
unique clinical dimension relevant to non-adherence. DAI-10 might be preferred for its 
simplicity and good psychometric properties (Nielsen et al., 2012) 
 
Compliance with medication and factors affecting compliance in Schizophrenia 
Compliance is the ability of the individual to follow health related advice, to take 
medication as prescribed, to attend scheduled appointment, and to complete recommended 
investigations.  Although the psychotropic drugs are effective in treating the mentally ill, 
it is also a well-documented fact that compliance among the patients with psychiatric 
disorders is poor.  A review of literature by Lacro et al., states that non-compliance to 
prescribed antipsychotic medication among schizophrenic patients is 41.2%(Lacro et al., 
2002)  In India, the rate of noncompliance with antipsychotic was estimated to be 38.7% 
(Baby, Gupta and Sagar, 2009).  
One of the major factors for hospitalization is found to be this noncompliance with 
psychotropic drugs . Non adherent patients are 3.7 times more likely to relapse than 
patients who take psychotropic medications as prescribed (Fenton et al., 1997) . Reviews 
have suggested that overall rates of partial medication adherence ranges from  41%-
55%(Lacro et al., 2002). 
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Antipsychotics have become the mainstay of treatment for schizophrenia and the 
maintenance of antipsychotic treatment has been shown to play a vital role in relapse 
prevention(Agostini JV, 2007).  
And despite advances in pharmacological approaches to therapy, the goal of long term 
success in the treatment of patients remains a significant challenge (Kane, 1999).  
Poor adherence to psychotropics undermines the possibility of effective drug treatment in 
psychiatric disorders. So medication compliance is one of the most difficult challenges in 
the management of schizophrenia. According to Cooper, (2007) the reasons for not taking 
medications as prescribed were forgetting, losing, running out, thinking medication is 
unnecessary, reluctance to take drugs and development of side effects(Cooper et al., 
2007).  Other reasons for noncompliance could be violence, greater substance use, 
complexity of the prescription, patient’s clinical features and relapses(Llorca et al., 
2005)(Ascher-Svanum et al., 2006) 
In developing countries like India the main reason for non-compliance may be 
affordability of medication, especially among the poor patients.  For them at times it may 
be difficult to decide which is more important, food or medicines. The accessibility to 
medical care, the cost of travel to reach the treatment facility may at times be the reason 
for stopping medication even when the medicines are provided free  (Prakash, 2007). Non 
compliance affects the course of illness, occupation, social skills and interpersonal 
relationships, eventually resulting in poor quality of life(Amador, 2006). So it is evident 
that functional level of the individual is affected due to noncompliance.      
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Studies on the variables affecting medication non-adherence have found that medication 
non-adherence along with medication related side effects are contributory. The correlation 
between awareness of mental illness and adherence with medication was highly 
significant in the study by Trauer and Sacks (2000).  The lack of insight was an important 
cause of    discontinuation(Fenton et al., 1997) . Lacro et al , (2002) reported that 10 out of 
14 studies that examined awareness of illness and medication non-adherence in patients 
with schizophrenia reported that awareness of illness are strongly correlated (Lacro et al., 
2002).  
Even with antipsychotic medication, however the probability of readmission within two 
years after discharge from the first hospitalization is about 0% to 60% (Sadock & Sadock, 
2007). Following discontinuation of medications, the relapse rate is about 80% within two 
years(National Institute of Mental Health, 2007). In schizophrenia, more than half of the 
patients have been noncompliant, leading to relapse, rehospitalization or poor outcome 
leading to high costs(Perkins, 2002).  
 
Compliance with antipsychotics is essential to prevent relapse and this compliance is 
influenced by several factors including attitude towards treatment(Löffler et al., 2003), 
side effects of the drugs (Khalkho and Khess, 1999) and their perceived benefit of 
medication(Fujikawa et al., 2008) .  
 
Antipsychotics have been associated with a wide range of side effects such as 
anticholinergic, extrapyramidal, hormonal and cardiovascular symptoms. Amador (2006) 
explains that nearly 60% of the patients with schizophrenia will be unaware of being ill. 
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This symptom predisposes the individual to non-compliance to treatment and increases 
the number of hospital readmission. Therefore these factors should be considered while 
health educating the patient on compliance.   
 
Lack of insight and a nonfavorable attitude to medication have been shown to be the two 
important factors contributing to treatment non-compliance(Freudenreich and Cather, 
2012)  along with medication related side effects. Another reason for nonadherence in 
patients with schizophrenia who lack insight is loss of decision-making capacity. It is 
extremely difficult to decide for themselves whether to take medicines for their mental 
condition and they cannot decide whether or not to use it (Fortinash, 2008). Hence, it is 
very important to know how much insight is affecting the life ofan individual with 
schizophrenia. 
Along with  a good therapeutic relationship and  a non-judgmental approach , the 
realization that compliance requires constant effort   is also needed for ensuring treatment 
adherence. (Goff et al., 2010).  
 
Insight and Medication Adherence:  
Cross-sectional studies of the relationship between insight and adherence to treatment 
have reported that increased insight was associated with greater treatment adherence. 
However, studies that examined the predictive power of insight and future treatment 
adherence have yielded mixed results with some studies finding no association while one 
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smaller study reported only a positive trend. Studies that investigated the association 
between change in insight and change in medication adherence over time are very few. 
Kampmon (2002) conducted a study to explore the indicators of compliance among first 
episode psychosis patients. The data was collected from the patients and also from the 
chart during the first three months following discharge(Kampman et al., 2002). The 
findings showed  that non compliance was due to harmful side effects, male sex, lack of 
social activities, low score on PANSS positive symptoms, high score on PANSS total 
score and young age. They concluded that insight and attitudes towards treatment are the 
important  determinants of compliance during the acute phase of psychosis. Adherence to 
medication is influenced by a variety of factors. These factors range from patient’s 
concerns about  the immediate positive consequences of medication intake, the wish to 
avoid negative consequences like relapse leading to re-hospitalisation and the attitude of 
significant others towards treatment.  
It is suggested that treatment strategies addressing adherence enhancement in 
schizophrenia may profit by considering both the patient's subjective adherence attitude 
profile as well as the specific pattern of risk factors for noncomplianceo including 
depression, lack of insight, negative syndrome, cognitive disorganization and socio-
demographic factors, which are differentially associated with each adherence attitude 
profile(Beck et al., 2011). 
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Measurement of Adherence  
Schizophrenic patients' self-reports of their experience of neuroleptic treatment were used 
as the basis for the construction of a scale predictive of drug compliance. Reliability 
analysis of the responses of 150 patients indicated high internal consistency in the 30-item 
scale, and preliminary validation in the form of discriminant classification accurately 
assigned 89% of the sample to complaint and non-compliant groupings. Both discriminant 
and factor analyses suggest that maximum variability in responding is accounted for by 
items reflecting how the patient feels on medication, rather than what he knows or 
believes about medication.(Hogan et al., 1983)  
Adherence to medciation among patients with Schizophrenia can be monitored by a 
variety of methods ranging between patient self-reports, clinician rating scales, pill count 
and the Medication Event Monitoring System. With regards to the relationship between 
attitude to medication and adherence, the study by Yang et al ( 2012),found that DAI 
score was higher in adherent patients when compared with the non adherent patients(Yang 
et al., 2012). The severity of the symptoms as measured by PANSS to were found to 
affect the adhrence to medication.   
 
Insight and Psychoeducation 
Psychoeducation  decreases relapse, readmission, encouragses treatment compliance , and 
reduce the length of hospital stay.  Psychoeducation is cost effective and clinically 
beneficial  (Xia et al., 1996).  
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The effect of psychoeducation on insight has been found to be a positive one with an 
increase in the level of insight among patients who received intervention. This 
improvement further led to better adherence to medication and an overall better 
outcome(Rathod et al., 2005) 
 
Rationale for the Study 
Schizophrenia is a heterogeneous condition with variable outcome.  Many factors affect 
the treatment and prognosis of patients with schizophrenia. Some of these factors of 
clinical relevance are insight, psychopathology, attitude to medication and medication 
adherence. These are also potential areas of change with treatment. This study was an 
attempt to measure  these four components and to determine the factors associated with 
each of them in patients with chronic schizophrenia. The second objective was to assess 
the correlation of these factors with each other.   
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AIMS AND OBJECTIVES 
 
Primary Objectives and aims of study  
1. To assess the level of insight and attitude towards medication in patients with 
chronic Schizophrenia. 
2. To determine factors associated with insight and attitude to medication in patients 
with schizophrenia. 
3. To determine the relationship between insight and attitude to medication in this 
group of patients with schizophrenia.   
 
Secondary objectives and aims of study  
1. To assess the level of associated factors like psychopathology and compliance 
with medication in patients with chronic Schizophrenia. 
2. To determine the relationship between psychopathology, insight, attitude to 
medication and compliance with medication in this group of patients with 
schizophrenia.   
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 METHODOLOGY AND MEASURES         
This chapter deals with research design, setting of the study, population, sample size, 
sampling method and criteria, data collection procedure, instruments and ethical issues. 
 Research design: 
Cross sectional study design was employed to determine the relationship of insight,  
psychopathology, attitude to medication and medication adherence in schizophrenia. 
Setting of the study:  
 This study was conducted in the Department of Psychiatry, Christian Medical College 
(CMC), Vellore, a tertiary care psychiatric facility. There are three adult psychiatric units 
and one child and adolescent psychiatric unit. The inpatient setting consists of 122 beds. 
The out patient services for new cases are available from Monday to Saturday in the 
morning, while old patients are reviewed four days a week from Monday to Thursday. 
About 350-400 old patients attend outpatient services for review on a regular basis.  
Among them approximately 50-60% of patients have a diagnosis of schizophrenia.   
Population:   
 The study population consists of patients diagnosed with schizophrenia (according to ICD-10    
criteria) attending the outpatient services at the Department of Psychiatry, CMC, Vellore. 
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Sample: 
101 patients who fulfilled the inclusion and exclusion criteria were recruited from the outpatients 
attending the Department of Psychiatry, CMC, Vellore. 
 
Sample size estimation:  
The sample size was calculated using the formula of one sample proportion, by keeping 
the prevalence of insight in schizophrenia as 50% and the precision as 10% with 5% alpha 
error and 80% of priori power. It  was calculated as  100 subjects with schizophrenia. 
(Saravanan et al., 2007)  
 
Sampling technique: 
The investigator used consecutive sampling technique. From patients attending outpatient 
services for review all who fulfilled the eligibility criteria were assessed for possible 
recruitment in this study.  
Criteria for sample selection: 
Inclusion Criteria:        
• ICD-10 diagnosis of Schizophrenia :duration 2yrs and above  
• Age above 18 years 
• Patients who are fit to give an informed consent. 
• Subjects who speak Tamil or English 
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 Exclusion Criteria: 
• Patients with severe language, hearing or cognitive impairment or patients having 
difficulty to give informed consent.  
• Subjects with a primary mood disorder or organic disorder.  
Description of the instruments 
Part 1: Socio demographic variables and clinical variables. (Appendix No.2) 
This part had two sections. 
Section A: Socio-demographic variables: This comprises of  age, sex, educational status, 
years of education, marital status, religion, residence, employment and socioeconomic 
status.  
Section B: Clinical data such as subtype of schizophrenia, duration of illness, course of 
illness, age at onset of illness, age at first contact, medical comorbidity, comorbid 
substance use , score on  PANSS (Positive and Negative Symptom Scale) and  family 
history of mental illness. 
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PANSS Scale: (Appendix No.4) 
Positive And Negative Symptom Scale, developed by Kay et al, comprises of 30 items is a 
freely available and standardized scale that is specifically developed to assess the 
psychopathology in patients with schizophrenia.(Kay, Oper & Linden Mayer, 1988). It 
has three subscales- 
Positive subscale consisting of 7 symptoms  
Negative subscale consisting of 7 symptoms  
General psychopathology subscale consisting of 16 symptoms. 
Each item is individually scored as 1-7 depending upon the severity:  
1= Absent  
2=Minimal; it denotes questionable, subtle or suspected pathology or extreme end of the 
normal range. 
3= Mild, indicative of symptom whose presence is clearly established but not pronounced 
and interferes little in day to day functioning.  
4= Moderate , characterizes a symptom which though representing  a serious problem, 
either occurs only occasionally or intrudes on daily life only to a moderate extent.  
5= Moderately severe, indicates marked manifestations that distinctly impact on one’s 
functioning but are not all consuming and usually can be contained at will.  
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6= Severe, represents gross pathology that is present very frequently, proves highly 
disruptive to one’s life, and often calls for direct supervision.        
7 =Extreme, refers to the most severe level of psychopathology, whereby the 
manifestations drastically interfere in most or all major life functions, typically 
necessitating close supervision and assistance in many areas.  
 
Scoring and interpretation 
The total items in this scale are 30. The range of possible score is 30-210. The scoring was 
done on the basis of absence or presence of symptoms in patients.  
The PANSS scale was tested for its validity and reliability. Cronbach’s score  reported in 
the literature for this scale was 0.80, which showed a good internal consistency.  
The scores are interpreted as follows: 
30                        Absence of symptoms 
31-74                   Mildly ill      
75-119                 Moderately ill 
120-164               Markedly ill 
164  and above    Severely ill  
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Part 2: Assessment of attitude 
Attitude to medication to be assessed using Drug Attitude Inventory (DAI) 
Drug Attitude Inventory (DAI) scale: (Appendix No.6) 
DAI -10 is a 10 item scale to assess how the attitude of schizophrenia patients towards 
their medication may affect compliance (Hogan, Awad  and Esatwood, 1983). The scale 
has been shown to have test- retest reliability, high internal consistency and discriminant, 
predictive and concurrent validity. This self report scale has ten items that the patient 
scores as True or False.  For six of the items (1,3,4,7,9 and 10), a True response is 
considered positive, whereas for the other four items (2,5,6 and 8), a False response is 
considered positive.  A positive answer is scored as +1 and a negative answer as -1. The 
final score is the sum of the ten scores.  
Interpretation of DAI score: 
Positive score -    Positive subjective response (favourable attitude) 
Negative score-   Negative subjective response (unfavourable attitude) 
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Part 3: Assessment of insight 
Schedule for Assessment of Insight: Expanded Version (SAI-E) (Appendix No.7) 
The expanded version of the Schedule for Assessment of Insight has been applied widely 
in Western and non Western countries for the assessment of insight.(Kemp, R. and David, 
A., 1997)  
 
It comprises questions to assess three dimensions of insight: awareness, relabeling of 
symptoms and adherence, plus labeling a hypothetical contradiction item added to 
evaluate the person’s capacity to consider other’s perspective. Each dimension comprises 
two or three questions which are scored on a 3 point scale from 0 (no insight) to 2 (good 
insight).  The supplementary question is scored from 0-4 and this is added to the total 
score. This expanded version also includes items on awareness of change, difficulties 
resulting from the psychiatric condition and insight into key symptoms (Kemp and David, 
1997). The maximum score is 35. 
 
The scores are interpreted as follows: 
Poor insight       < 15 
Moderate insight 15.1- 24.9   
Good insight   >25  
	   31	  
 
Validity and reliability 
 The SAI-E has been demonstrated to have high concurrent validity with other 
measures of insight, namely the insight question of the PANSS (r= 0.895), the Insight and 
Treatment Attitude Questionnaire (r=0.845) and the Schedule for the Assessment of 
Insight (SAI)  (r= 0.977) 
Part 4: Assessment of compliance: 
Compliance to be assessed with Morisky scale and by chart review.  
MORISKY SCALE: (Appendix No.5) 
It was developed by Morisky, Gree and Levine in 1986(Morisky et al., 2008) and contains 
four yes or no type questions. Each answer indicating compliance was given a score of 0 
and each answer indicating noncompliance was given a score of 1. Concurrent and 
predictive validity of a structured four item self-reported adherence measure (alpha 
reliability =0.61). 
Interpretation: 
Interpretation: 
 Score 1 point for every YES answer  
0 points = high adherence  
1-2 points = intermediate  
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3-4 points = low adherence 
All those who had a total score of 0 are considered compliant while those with a score of 
1 or more are considered non compliant. 
 
Chart review for compliance: 
Question 1. Has the patient been compliant with medication over the past one year?  
Question 2.Has the patient been compliant with medication throughout his or her illness? 
Scoring: ‘1’ mark was given for compliance and ‘0’ mark for non-compliance.   
 
Statistical methods:  
We used descriptive statistics to describe continuous variables and frequency distributions 
for categorical variables. Descriptive statistics was employed to assess the socio- 
demographic variables, clinical variables, compliance, psychopathology, insight and 
attitude.  Frequencies were calculated for the categorical variables and means as well as 
the standard deviations were calculated for the continuous variables. Chi-square test for 
association was used to determine the association of compliance with the selected socio-
demographic and clinical variables. Data were analyzed with SPSS 17.0. 
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Protection of human rights: 
The Institutional Review Board of the Christian Medical College, Vellore, approved the 
study protocols.  The investigator explained the purpose of the study and information 
leaflets (Appendix No.1) were also issued to them.  Informed consent (Appendix No.3) 
was obtained from all subjects and their caregivers. The confidentiality and the autonomy 
of the subjects were respected.  
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RESULTS 
I. Demographic details of study sample 
The sample comprised of forty men (39.6 percent) and sixty one (60.4 percent) 
women with chronic schizophrenia (Figure 1).  
gender
female
male
	  
Figure	  1:	  Sex	  distribution	  of	  study	  participants	  
	  
The mean age of the study sample was 35.1 years (SD: 8.8 years). The mean age 
of women was 36.3 (SD: 8.8 years) and the mean age for men was 33.3 years (SD: 8.6 
years). Majority were in the age group of 30 years to 39 years, followed by age group, less 
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than 30 years, followed by age group 40 years to 49 years. Least representation was from 
the older age group, 50 years and above. The age distribution is given in Table 1.    
	  
Table	  1:	  Details	  of	  age	  distribution	  of	  participants	  
	  
Age	  group	   Men	  
N	  (%)	  
Women	  
N	  (%)	  
Total	  
N	  (%)	  
≤	  29	  years	   15	  (37.5)	   15	  (24.6)	   30	  (29.7)	  
30years	  -­‐	  39years	   18	  (45.0)	   21	  (34.4)	   39	  (38.6)	  
40years	  -­‐	  49years	   4	  (10.0)	   19	  (31.1)	   23	  (22.8)	  
50years	  -­‐	  59years	   3	  (7.5)	   6	  (9.8)	   9	  (8.9)	  
Total	   40	  (100.0)	   61	  (100.0)	   101	  (100.0)	  
	  
	   Sixty nine percent of the participants were from rural area whereas the rest from 
urban area (Figure 2). Among men, seventy five percent were from rural area in 
comparison to sixty five percent among women.    
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Figure	  2:	  Place	  of	  residence	  of	  study	  sample	  
	   Majority of participants were married (sixty percent). A significant proportion of 
the study sample were still unmarried, thirty one percent. There were no widow/widower 
in the sample. Nine percent were either separated or divorced. There was significant 
gender difference in the marital status. Sixty five percent of men were unmarried whereas 
eighty four percent of women were married. The details are given in Table 2.  
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Table	  2:	  Marital	  status	  of	  sample	   	  
Marital	  status	   Men	  
N	  (%)	  
Women	  
N	  (%)	  
Total	  
N	  (%)	  
Single	   26	  (65.0)	   6	  (9.8)	   32	  (31.7)	  
Married	   9	  (22.5)	   51	  (83.6)	   60	  (59.4)	  
Separated/Divorced	   5	  (12.5)	   4	  (6.6)	   9	  (8.9)	  
Widow	   0	  (0.0)	   0	  (0.0)	   0	  (0.0)	  
Total	   40	  (100.0)	   61	  (100.0)	   101	  (100.0)	  
 
  
More than three quarter (eighty five percent) were followers of Hindu religion. Eleven 
percent were Christians and the rest (four percent) were Muslims.  There was no major 
gender difference in religious faith of study sample. 
	  
Table	  3:	  Religious	  faith	  of	  study	  participants	  	  
Religion	   Men	  
N	  (%)	  
Women	  
N	  (%)	  
Total	  
N	  (%)	  
Hindu	   34	  (85.0)	   52	  (85.2)	   86	  (85.1)	  
Christian	   4	  (10.0)	   7	  (11.5)	   11	  (10.9)	  
Muslim	   2	  (5.0)	   2	  (3.3)	   4	  (4.0)	  
Total	   40	  (100.0)	   61	  (100.0)	   101	  (100.0)	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II. Socio economic details of study sample 
Nine percent of the study sample was illiterate. Three fourth of the sample had 
high school or above educational status of which four percent had professional education 
and sixteen percent had graduate/postgraduate education. Overall, men had slightly higher 
level of education in comparison to women. The percentage of illiterate women was twice 
that of men (Table 4). 
Table	  4.	  Educational	  status	  of	  study	  participants	  
Religion	   Men	  
N	  (%)	  
Women	  
N	  (%)	  
Total	  
N	  (%)	  
Professional	   3	  (7.5)	   1	  (1.6)	   4	  (4.0)	  
Postgraduate/Graduate	   10	  (25.0)	   6	  (9.8)	   16	  (15.8)	  
Diploma	   11	  (27.5)	   10	  (16.4)	   21	  (20.8)	  
High	  school	   10	  (25.0)	   27	  (44.3)	   37	  (36.6)	  
Middle	  school	   3	  (7.5)	   8	  (13.1)	   11	  (10.9)	  
Primary	  school	   1	  (2.5)	   2	  (3.3)	   3	  (3.0)	  
Illiterate	   2	  (5.0)	   7	  (11.5)	   9	  (8.9)	  
Total	   40	  (100.0)	   61	  (100.0)	   101	  (100.0)	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Sixty percent (N=61/101) of the study sample were unemployed. The proportion 
of unemployed men was 30 percent (N=12/40) in contrast to eighty percent (N=49/61) of 
unemployed women (Figure 3.4).  
	  	  	  	  	  	  	  	  	  	  
Figure	  3:	  Employment	  status	  of	  men	  
employment status
SEX:         1   male
unemployed
employed
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  Figure	  3:	  Employment	  status	  of	  women	  
employment status
SEX:         2   female
unemployed
employed
	  
	   	  
	  
Further, occupation of the participants was analysed. The details of the occupation of 
study participants are given in Table 5. 
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Table 5: Occupation of study participants 
	  
Occupation	   Men	  
N	  (%)	  
Women	  
N	  (%)	  
Total	  
N	  (%)	  
Professional	   0	  (0.0)	   1	  (1.6)	   1	  (1.0)	  
Semiprofessional	   0	  (0.0)	   1	  (1.6)	   1	  (1.0)	  
Clerical/	   Shop	   owner/	  
Farmer	  
10	  (25.0)	   2	  (3.3)	   10	  (9.9)	  
Skilled	  worker	   3	  (7.5)	   0	  (0.0)	   3	  (3.0)	  
Semiskilled	  worker	   8	  (20.0)	   0	  (0.0)	   8	  (7.9)	  
Unskilled	  worker	   7	  (17.5)	   10	  (16.4)	   17	  (16.8)	  
Unemployed	   12	  (30.0)	   49	  (80.3)	   61	  (60.4)	  
Total	   40	  (100.0)	   61	  (100.0)	   101	  (100.0)	  
	  
	   Using Kuppusamy scale, the socioeconomic status of the study participants was 
assessed. Half of the participants (fifty five percent) belonged to lower socioeconomic 
strata and nearly the same proportion (forty seven percent) was in the middle 
socioeconomic strata. Only one participant was from the upper socioeconomic strata.  
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Table 6: Socioeconomic strata of study participants  
 
Socioeconomic	  status	   Men	  
N	  (%)	  
Women	  
N	  (%)	  
Total	  
N	  (%)	  
Upper	   0	  (0.0)	   1	  (1.6)	   1	  (1.0)	  
Middle	   20	  (50.0)	   28	  (45.9)	   48	  (47.5)	  
Lower	   20	  (50.0)	   32	  (52.5)	   52	  (51.5)	  
Total	   40	  (100.0)	   61	  (100.0)	   101	  (100.0)	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TABLE 1b: Clinical Variables 
VARIABLES N (%) 
AGE <=35 72(71.3) 
>=35 29(28.7) 
GENDER MALE 40(30.6) 
FEMALE 61(60.4) 
FAMILY 
HISTORY 
SCHIZOPHRENIA 18(17.8) 
MOOD DISORDER 
AND OTHERS 
22(21.8) 
NIL 61(60.4) 
MEDICAL 
CO 
MORBIDITY 
DIABETES 
DYSLIPIDEMIA 
14(14.9) 
HYPERTENSION/ 
CAD 
1(1) 
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OTHERS 6(5.9) 
NIL 80(79.2) 
SUBSTANCE 
USE 
ALCOHOL 3(3) 
TOBACCO 5(5) 
NIL 93(92.1) 
COURSE CONTINUOUS 86 (85.1) 
EPISODI 15(14.9) 
PANSS 
SEVERITY 
MILD 88 (87.9) 
MODERATE 13 (12.9) 
INSIGHT 
 
MODERATE 43 (42.6) 
GOOD 58 (57.4) 
MORISKY 
 
 
COMPLIANT 32 (31.7) 
NON COMPLIANT 69 (68.3) 
COMPLIANCE 
RATE 
COMPLIANT 68(67.3) 
NON COMPLIANT 33(32.7) 
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Table 1b: Clinical variables:  
Table 1b gives the details related to family history, medical co morbidity, substance use, 
course of the illness, PANSS scores, SAI-E scores, DAI scores, and compliance scores. 
Majority of the patients, 60% had their age less than 35 years and the remaining 40 % had 
their age above 35 years.  Majority of the patients 86(85.1%), had a continuous course of 
illness and the remaining had an episodic course.  Regarding the medical co morbidity 
obtained from the chart 14(14.9 % ) had history of  diabetes or dyslipidaemia, 1(1%) had 
hypertension, 6(5.9 %) had other medical disorders  and 80(79.2%)of the patients did not 
have any medical comorbidity.    
92% of the study population did not admit to any substance use. 5% of the group of  
patients with schizophrenia were using tobacco and 3% were using alcohol.  18% of the 
population had family history of schizophrenia, 2 % had family history of Mood disorder  
20 % had other psychiatric disorders. Majority, 60% had no family history of any 
psychiatric disorder.  
The PANSS scale assessed the severity of psychopathology. For the majority (87%) of the 
sample, total score was between 31 to 74 and was included in the mild category and for 
 
DAI 
 
FAVOURABLE 
 
96(95) 
NOT 
FAVOURABLE 
5(5) 
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13% of the sample the score was between 75 to 119 and were categorized as having 
moderate level of psychopathology. None of the study group had scores above 119, 
included in markedly ill or severely ill category. 
 Assessment of insight by SAI- E scale revealed that 57 % of the patients had good insight 
and 43 % had moderate insight.  As per the Drug Attitude Inventory 96 (95%) had a 
favourable attitude and 5(5%) had a not favourable attitude towards medication. 
Compliance as assessed by the Morisky scale showed that 32 % were compliant and 68 % 
were non compliant. However when the compliance was assessed by the chart review it 
was seen that only 33% were noncompliant and that the majority 67% was compliant. 
Table 2. Descriptive statistics 
Variable N Mean Std. Deviation 
Age in years 101 35.11 8.796 
Years of education 101 9.77 4.694 
PANSS Positive 101 11.51 5.128 
PANSS Negative 101 17.12 4.670 
PANSS General 101 29.40 7.2 
PANSS Total 101 58.04 13.7 
SAI E  101 25.02 4.366 
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DUP  62 18.05 32.256 
Age at onset in years 101 26.23 7.904 
 
Table 2 Descriptive statistics 
Distribution writing Results 
The mean age of the sample was 35 years and the standard deviation was 8.796. 
The mean years of education was 9.8 years and the SD 4.69. 
The mean PANSS positive score was 11.5 and the SD5.12 
The mean PANSS negative score was 17.12 and the SD 4.67 
The mean PANSS general score was 29.40 and the SD 7.2 
The mean PANSS total score was 58.04 and the SD 13.7 
The mean SAI E score was 25.2 and the SD 4.36 
The mean duration of untreated psychosis was 18 months and SD 32.2 
The mean age at onset was 26 years and the SD 7.9. 
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Table	  1.	  Details	  of	  natural	  history	  of	  schizophrenia	  
	  
Details	  of	  schizophrenia	  
	  
N	  
	  
Mean	  
	  
SD	  
	  
Age	  of	  onset	  
	  
101	  
	  
26.2	  years	  
	  
7.9	  years	  
Duration	   of	   untreated	  
psychosis	  
	  
62	  
	  
18	  months	  
	  
3.2	  months	  
	  
Duration	  of	  schizophrenia	  
	  
101	  
	  
8.9	  years	  
	  
6.2	  years	  
	  
Table	  2.	  Gender	  difference	  in	  age	  of	  onset	  of	  schizophrenia	  
	  
Details	  of	  schizophrenia	  
Men	  	  
(SD)	  	  
Women	  	  
(SD)	  
Age	  of	  onset	  of	  schizophrenia	   23.8	  years	  
(5.8	  years)	  
27.8	  years	  
(8.7	  years)	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Table	  3.	  PANSS	  score	  of	  study	  sample	  
	  
Details	  of	  schizophrenia	  
Men	  
(Median)	  
Women	  
(Median)	  
Total	  score	  
(Median)	  
PANSS	  	  
positive	  score	  
	  
10	  
	  
9	  
	  
10	  
PANSS	  	  
negative	  score	  
	  
18	  
	  
16	  
	  
17	  
PANSS	  	  
general	  psychopathology	  score	  
	  
29	  
	  
29	  
	  
29	  
PANSS	  	  
total	  score	  
	  
59	  
	  
55	  
	  
56	  
	  
Total	  sample	  
	  
N=40	  
	  
N=61	  
	  
N=101	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Figure 1. Insight in patients with schizophrenia assessment by SAI-E 
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Figure 1. Insight in patients with schizophrenia assessment by SAI-E 
This graph summarizes the findings from the administration of the Schedule for 
Assessment of Insight – Expanded version (SAI -E) to this study population of patients 
with schizophrenia.  
The schedule for assessment of insight expanded version assesses mainly three 
dimensions of insight. The awareness of the patient about the changes in him or her the 
attribution of these changes and the actions subsequent to it.  The first seven questions in 
the schedule assess the awareness, the next two questions the attribution and the last three 
the action. This graph shows the percentage of the scores the patients of this study 
population   scored in these different dimensions. In the dimension of awareness the 
patients of this study population scored 80% of the maximum score possible.  And the 
score in the dimension of attribution was 36 % of the maximum score possible, in this 
study population. In the dimension of action, the patients of this study population scored 
67 % of the maximum score.  
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TABLE 3a: Association between Socio demographic variables  and Psychopathology 
and Insight. 
SOCIODEMOGRAPHIC 
VARIABLES 
ASSESSMENT TOOLS 
PANSS 
 
SAI-E 
 
Mild(n=88
) 
Moderat
e(n=13) 
P 
value 
Moderat
e(n=43) 
Good(n=
58)) 
P 
value 
AGE(Years) <=35(n=61) 51(83.6%) 10(16.4
%) 
 30(49.2
%) 
31(28.4
%) 
0.097 
>35(n=40) 37(92.5%) 3(7.5%) 0.192 13(32.5
%) 
27(67.5
%) 
 
Gender Male(n=40) 34(85.0%) 6(15.0%) 0.605 16(40.0
%) 
24(60.0
%) 
0.672 
 
Employment 
status 
 
Employed(n=40) 
 
35(87.5%) 
 
5(12.5%) 
 
0.928 
 
19(47.5
%) 
 
21(52.5
%) 
 
0.418 
 
Unemployed(n=61) 53(86.9%) 8(13.1%) 24(39.3
%) 
37(60.7
%) 
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Socio-Economic 
Class 
Upper(n=1) 1(100%) 0(0%) 0.705 0(0%) 1(100%) 0.232 
Middle(n=48) 43(89.6%) 5(10.4%) 17(35.4
%) 
31(64.6
%) 
Lower(n=52) 44(84.6%) 8(15.4%) 26(50%) 26(50%) 
Residence Rural(n=70) 62(88.6%) 8(11.4%) 0.515 30(42.9
%) 
40(57.1
%) 
0.931 
Urban(n=31) 26(83.9%) 5(16.1%) 13(41.9
%) 
18(58.1
%) 
Marital status Single(n=32)  25(78.1%) 7(21.9%) 0.130 13(40.6
%) 
19(59.4
%) 
0.309 
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TABLE 3a: Association between Socio demographic variables  and Psychopathology 
and Insight. 
Positive and negative syndrome scale (PANSS) for schizophrenia and socio 
demographic variables 
Age: In this study population of patients with schizophrenia in those aged 35 or below the 
patients with mild severity of psychopathology as per PANSS were 51 (83.6%) and those 
with moderate psychopathology were 10 (16.4%). In this study population of patients with 
schizophrenia in those aged 35 or above the patients with mild severity of 
psychopathology as per PANSS were  37 (92.5%) and those with moderate 
psychopathology were 3 (7.5%). 
Gender: In the men of this study population of patients with schizophrenia 34 (85%) had 
mild severity of illness in the PANSS scale and 6(15%) had moderate severity.  In the 
women of this study population 54(88.5%) had mild severity of illness in the PANSS 
scale and 7 (11.5%) had moderate severity. P value 0.605 
Employment : In this study population of patients with schizophrenia the severity of 
psychopathology as assessed by the PANSS was mild in  35(87.5% ) and moderate in 
5(12.5%) of the employed. In the unemployed, the mild severity was seen in 53 (86.9% ) 
and moderate severity in 8 (13.1%). P value: 0.928 
Socioeconomic class:  In this population of patients with schizophrenia the association of 
severity of psychopathology was mild in 1 (100%) and moderate in 0(0%) of the upper 
class. In  the middle class 43 (89.6%) had mild severity  and 5(10.4%) had moderate 
	   55	  
severity. I n the lower class 44(84.6%) had mild severity and 8(15.4% had moderate 
severity. P value: 0.705 
Residence: In this study population of patients with schizophrenia , among those residing 
in rural areas and in 62(88.6%) had mild severity and 8(11.4%) had moderate severity. 
26(83.9%) of those residing in the urban areas had mild severity and 5(16.1) of them had 
moderate severity. 
P value: 0.515 
Marital :In this population of patients with schizophrenia among the single, 25(78.1%) 
had mild severity and 7 (21.9%) had moderate severity of psychopathology. In the 
married 54 (90.0) had mild severity , and 6 (10%) had moderate severity of 
psychopathology. Mild psychopathology was seen in 9(100%) of the divorced/separated 
whereas, none of them had moderate level of psychopathology.   
P value:0.130 
Schedule for assessment of insight – expanded version (SAI-10) and 
sociodemographic variables: 
Age: In this study population of patients with schizophrenia assessment of insight by  
SAI- E scale revealed that in those aged 35 or below, 30(49.2%)  had moderate insight 
and 31 (28.4%) had good insight. In those aged above 35 years 13(32.5%) had moderate 
insight and 27(67.5%) had good insight. P value:0.097 
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Gender:  
Of the male patients of this study population16 (40%) had moderate insight as per the SAI 
–E scale whereas 24 (60%) had good insight. And of the female patients of this study 
population  27 (44.3%) had moderate insight as per the SAI –E scale and  34 (55.7%) had 
good insight. 
P value 0.672 
 
Employment status: 
Among the employed 19(47.5%) had moderate insight as assessed by SAI-E and 24(60%) 
had good insight. 24(39.3%)  of the unemployed had moderate insight whereas, 
37(60.7%) of them had good insight. 
Socioeconomic class: Among the upper class, insight as assessed by SAI-E was found to 
be moderate in 0(0%) and good in 1 (100%). Insight was moderate in 17(35.4%) and good 
in 31(64.6%) of the middle class population. In the lower class 26(50%) had moderate 
insight and 26(50%) had good insight. 
Area of  Residence  
 In this study population of patients with schizophrenia 30(42.9%) of those residing in 
rural areas had moderate insight and 40 (57.1%) had good insight. Among the people 
hailing from urban areas 13(41.95) had moderate insight and 18 (58.1%) had good insight 
P value :0.931  
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Marital Status 
In this study population of patients with schizophrenia 13(40.6%) of those who are single 
had moderate level of insight and 19 (59.4%) had good insight. 24(40%) of those married 
had moderate insight and the insight was good in 36(60%) of them. In the 
divorced/separated 6(66.7%) had moderate insight and 3 (33.3%) had good insight. 
 
TABLE 3b: Association between Socio demographic variables and Attitude to 
medication and      Compliance 
SOCIODEMOGRAPHIC 
VARIABLES 
ASSESSMENT TOOLS 
DAI 10 MORISKY  
Favourabl
e(n=96) 
Not 
Favourabl
e(n=5) 
P 
value 
Compliant 
 (n=32) 
Non 
complian
t 
(n=69) 
P 
value 
AGE(Years) <=35(n=61) 58(95.1%) 3(4.9%)  19(31.1%) 42(68.9
%) 
0.886 
>35(n=40) 38(95%) 2(5%) 0.985 13(32.5%) 27(67.5
%) 
 
Gender Male(n=40) 37(92.5%) 3(7.5%) 0.339 14(35.0%) 26(65.0
%) 
0.562 
Female(n=61) 59(96.7%) 2(3.3%) 18(29.5%) 43(70%) 
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Employment 
status 
Employed(n=40) 38(95%) 2(5%) 0.985 13(32.5%) 27(67.5
%) 
0.886 
 
Unemployed(n=61) 58(95.1%) 3(4.9%) 19(31.1%) 42(68.9
%) 
 
 
 
Socio-
Economic 
Class 
 
 
 
Upper(n=1) 
 
 
 
1(100%) 
 
 
 
0(0%) 
 
 
 
0.836 
 
 
 
0(0%) 
 
 
 
1(100%) 
 
 
 
0.762 
Middle(n=48) 45(93.8%) 3(6.2%) 16(33.3%) 32(66.7
%) 
Lower(n=52) 50(96.2%) 2(3.8%) 16(30.8%) 36(69.2
%) 
Residence Rural(n=70) 68(97.1%) 2(2.9%) 0.145 20(28.6%) 50(71.4
%) 
0.312 
Urban(n=31) 28(90.3%) 3(9.7%) 12(38.7%) 19(61.3
%) 
Marital status Single(n=32)  29(90.6%) 3(9.4%) 0.344 12(37.5%) 20(62.5
%) 
0.663 
Married(n=60) 58(96.7%) 2(3.3%) 17(28.3%) 43(71.7
%) 
Divorced/separated 
(n=9) 
9(100%) 0(0%) 3(33.3%) 6(66.7%) 
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TABLE 3b: Association between Socio demographic variables and Attitude to 
medication and Compliance 
Drug attitude inventory (DAI) and socio demographic variables: 
Age:  In this study population of patients with schizophrenia in those aged 35 or below 
the patients with a favourable attitude to medication constituted 58(95.1%) and those with 
a not favourable attitude were 3(4.9%). In this study population of patients with 
schizophrenia in those aged more than 35 years the patients with a favourable attitude to 
medication constituted 38(95%) and those with a not favourable attitude were 2(5%) 
P value: 0.985 
Gender 
Of the male patients of this study population of patients with schizophrenia 37(92.5%) 
had a favourable attitude towards medication whereas 3(7.5%) had a not favourable 
attitude. 
And of the female patients of this study population  59(96.7%) had a favourble attitude 
and 2(3.3%) had a not favourable attitude 
P value: 0.339 
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Employment: 
38(95%) of the employed had a favourable attitude towards medication as assessed by 
DAI 10, whereas 2(5%) of them had a not favourable towards medication. Of the 
unemployed, 58(95.1%) had a favourable attitude, whereas, 3 (4.9%) had a not favorable 
attitude. 
P value:0.985 
Socio Economic Class: In the upper class 1(100%) had a favourable attitude towards 
medication and 0(0%) had a not favourable attitude. 45(93.8%) of the middle class had a 
favourable attitude and 3(6.2%) had a not favourable attitude. In the lower economic class 
50(96.2%) had a favourale attitude, 2(3.8%) had a not favourable attitude. Pvalue: 0.836 
Area of Residence: 
In those hailing from the rural areas 68(97.1%) had a favorable attitude whereas 2(2.9%) 
had a not favourable attitude. 28(90.3%) of the urban had a favourable attitude and 3(9.7 
%) had a not favourable attitude. 
Pvalue: 0.145 
Marital Status: 
Among the single 29(90.6%) had a favourable attitude and 3 (9.4%) had a not favourable 
attitude. Of the married 58(96.7%) had a favorable attitude and 2 (3.3 %) had a not 
favourable attitude. Among the divorced/separated 9(100%) had a favourable attitude 
towards medication, and 0(0%) had a not favorable attitude. Pvalue : 0.344 
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Morisky scale and socio demographic variables: 
Age : In this study population of patients with schizophrenia in those aged 35 or below 
the number of  patients who were compliant with medication was  19(31.1%) and those 
with poor compliance were 42(68.9%). In this study population of patients with 
schizophrenia in those aged 35 or above  the patients  who were compliant with 
medication was  13(32.5%) and those with poor compliance were 27(67.5%) as per the 
Morisky scale. P value: 0.886 
 
Gender:   
Of the males 14(35%) compliant and 26 (65 %) were noncompliant as per the Morisky 
chart. 18 (29.5 %) of the women were compliant and 43 (70.5 %) were noncompliant.  
P value 0.562 
Employment status: 
Of the employed , 13(32.5%) were compliant with medication, whereas  27(67.5%) were 
not compliant with medication. Of the unemployed, 19(31.1%) were compliant and 
42(68.9%) were not compliant with medication. 
P value: 0.886 
Socio economic class:  
Among the upper socioeconomic class , 0(0%) was compliant with medication, and 
1(100%) was not compliant with medication. In the middle class population, 16(33.3%) 
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were compliant with medication, and 32(66.7%) were not compliant with medication. In 
the lower class population 16(13.8%) were compliant with medication, and 36(69.2%) 
were not compliant with medication. 
Pvalue: 0.762 
 
Area of Residence: Among people residing in the rural area 20(28.65) were compliant 
with medication and 50(71.4%) were not compliant with medication. 
Among those residing in the urban area 12(38.7%) were compliant with medication and 
19(61.3%) were not compliant with medication. Pvalue:0.312 
 
Marital status : Among the people who were single 12(37.5%) were compliant whereas 
20 (62.5%) were not compliant with medication. 17(28.3%) of the married were 
compliant and 43(71.7%) were not compliant with medication as per Morisky scale. 
Among the divorced/separated, 3(33.3%) were compliant with medication whereas 
6(66.7%) were not compliant with medication.  P value: 0.663 
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TABLE 4a: Association between Psychopathology, Insight, Attitude to medication 
and Compliance to medication 
ASSESSMENT TOOLS COMPLIANCE WITH MEDICATION 
MORISKY CHART REVIEW 
Compliant 
(n=32) 
Non 
compliant 
(n=69) 
P 
value 
Complia
nt 
(n=68) 
Non 
compli
ant 
(n=33) 
P 
value 
PANSS 
(Psychopatholog
y) 
Mild(n=88) 31(35.2%) 57(64.8%
) 
0.046 63(71.6
%) 
25(28.
4%) 
0.047 
Moderate(n=13) 1(7.7%) 12(92.3%
) 
 5(38.5%) 8(61.5
%) 
 
SAI-E 
(Insight) 
Moderate(n=43) 11(25.6%) 32(74.4%
) 
0.256 28(61.5
%) 
15(34.
9%) 
0.683 
Good(n=58) 21(36.2%) 37(63.8%
) 
40(69%) 18(31.
0%) 
DAI 10 
(Attitude) 
Favourable(n=96) 32(33.3%) 64(66.7%
) 
0.118 66(68.8
%) 
30(31.
2%) 
0.683 
Not 
Favourable(n=5) 
0 5(100%) 2(40%) 3(60.0
%) 
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Table 4a:Severity and compliance 
Severity and compliance using Morisky scale. 
In this study population, those patients with mild severity 31 (35.2%) were compliant  
whereas  57 (64.8%) were noncompliant. 
In those with moderate severity 1 ( 7.7%)  was compliant whereas  12 (92.3%) were non- 
compliant. 
P value 0.046   
Severity using chart review 
In those patients with mild severity 63 (71.6 %)  were compliant  whereas 25 (  28.4%) 
were noncompliant 
In those with moderate severity 5 (38.5 %) were compliant whereas 8 ( 61.5 %) were non- 
compliant. 
P value 0.017   
Insight and compliance 
Insight and compliance according to Morisky scale 
In those patients with moderate insight 11 ( 25.6 %) were compliant  whereas 32 (74.4 %)  
were noncompliant 
In those with good insight 21 (36.2 % ) were compliant whereas 37 ( 63.8 %)  were non- 
compliant. P value   0.256 
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Insight and compliance according to Chart review 
In those patients with moderate insight  28 (65.1 %)  were compliant  whereas 15 (34.9  
%)  were noncompliant 
In those with good insight  40 (69.0 %) were compliant whereas 18 (31%) were non- 
compliant. 
P value   0.683 
Attitude and compliance 
Compliance as per the Morisky scale 
In those with a favourable attitude 32 (33.3  %)  were compliant with medication whereas 
64(66.7 %)  were non compliant. 
In those with a not favourable attitude to medication  none  (0%)  was  compliant with 
medication and  5 ( 100%)were not compliant with medication.  
P value 0.118 
Compliance as per the chart review 
In those with a favourable attitude  66(  68.8%)  were compliant with medication whereas 
30 (31.2 %)  were non compliant. 
In those with a not favourable attitude to medication  2  (40%)  was  compliant with 
medication and   ( 60%)were not compliant with medication. P value 0.181 
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TABLE 4b: Association between Psychopathology , Insight and Attitude to 
medication 
ASSESSMENT TOOLS DAI 10(Attitude) P value 
Favourable(n=96) Not Favourable(n=5) 
PANSS 
(Psychopathology) 
Mild(n=88) 86(97.7%) 2(2.3%) 0.001 
Moderate(n=1
3) 
10(76.9) 3(23.1%)  
SAI-E 
(Insight) 
Moderate(n=4
3) 
39(90.7%) 4(9.3%) 0.083 
Good(n=58) 57(98.3%) 1(1.7%) 
 
Table 4b: Association between psychopathology, insight and attitude to medication 
Among the patients who had mild psychopathology as per the PANSS scale, 86(97.7%) 
had a favourable attitude towards medication, and 2(2.3%) had a not favourable attitude 
towards medication. Of the patients who had a moderate psychopathology 10(76.9%) had 
a favourable attitude towards medication whereas, 3(23.1%) had a not favourable attitude 
towards medication. 
P value: 0.001 
Among the patients who had moderate insight as per SAI-E , 39 (90.7%) had a favourable 
attitude towards medication, and 4( 9.3%) had a not favourable attitude towards 
medication. 
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57(98.3%) of the patients with good insight had favourable attitude towards medication 
whereas, 1( 1.7%) had a not favourable attitude towards medication. 
Pvalue: 0.007  
 
TABLE 4c: Association between Psychopathology and Insight 
ASSESSMENT TOOLS SAI-E 
(Insight) 
P value 
Moderate(n=43) Good(n=58) 
PANSS 
(Psychopatholog
y) 
Mild(n=88) 33(37.5%) 55(62.5%) 0.007 
Moderate(n=13) 10(76.9%) 3(23.1%)  
 
Table 4c: Association between psychopathology and insight 
Of the patients with mild severity of psychopathology as per PANSS scale, 33 (37.5%) 
had moderate level of insight and 55(62.5%) had good level of insight. Of the patients 
with moderate psychopathology 10(76.9%) had moderate insight, and 3(23.1%) had good 
insight. 
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DISCUSSION  
Previous studies have documented the inverse relationship between psychopathology and 
Insight (Saravanan et al., 2007)(Amador, XF and David, AS., 1998). However, the study 
by Johnson et al.  shows that the relationship between psychopathology and insight is not 
static.   The earlier were  cross-sectional and the study by later is a cohort study. They 
found that psychopathology, insight and explanatory models changed over the 5-year 
period. 
Among this group of patients with chronic schizophrenia the majority of patients (60%) 
attending the review OPD were less than 35  and the mean age was 35.  
Among this group of patients with chronic schizophrenia the majority of patients 
attending the review OPD were women.  
Sixty percent of the study population was unemployed. The housewives were entered as 
unemployed and this may be one reason for this finding. 99% of the population belonged 
to the lower or middle socioeconomic class. This may due to various factors and may be 
reflecting the general population attending the hospital and may have to be compared with 
the population of acute patients who come to the OPD.  
 Among the group none of the patients was widowed. It may be that the widowed are not 
attending the review OPD, or are doing well. The support may be absent after the death of 
the spouse and they may not be coming of brought to the hospital. And only 9 % were 
divorced or separated, indicating a tendency of increased tolerance towards patients who 
are only mildly or moderately ill and having moderate to good insight.    
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In both the groups (85% in males and 89 % in females) the majority of patients had mild 
illness. 
All the patients came under either mild or moderate severity (p value 0.605). The majority 
of the patients in this group came under the category of mild psychopathology as per the 
total score in the PANSS scale.  The  psychopathology as assessed by the PANSS scale 
was either mild for 87% of patients and moderate for 13% of patients. None of the 
patients came under other categories of psychopathology absent, markedly ill and severely 
ill. Possible reasons for this could be that those who improved with treatment attended 
medical care on a regular basis in comparison to those who did not improve with 
treatment.  
According to the SAI E scale majority of the patients had good insight. No patient scored 
poor in insight. Cause for this finding could be that those with poor insight are possibly 
taken care by the family members and are not attending the medical care facility regularly. 
Compliance as assessed by the Morisky scale(Morisky et al., 2008)  showed that 32 % 
were compliant and 68 % were  non compliant. In spite of the patients having good insight 
the compliance remains a problem.  Cause for the inconsistany between the attitude 
towards illness as reflected in the insight and practice of regular intake of medication 
could be analyzed and specific interventions targeted at improving compliance. Financial 
or other  problems which could contribute towards reason for noncomplianc  may  be 
addressed with the family or support group.  
The chart review showed that only 33% were noncompliant and that the majority 67% 
was compliant. The discrepancy between the two scales can be interpreted in different 
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ways. The Morisky is a self rated scale. The chart shows what the patient or carer reports 
with at times the impression of the therapist based upon the regularity for review, 
presence or absence of side effects etc,. 
The majority of the patients (60 %) were below the age of 35yrs which was the  mean age  
for the group. The age at first contact was less than 35yrs for 71% of patients and more 
than 35  for  29 % of patients  The mean age of contact was 30 years. 
The majority (85%) of patients had a continuous course of the disorder, schizophrenia. 
The patients who recover or who remit may be coming to review less often.  They may be 
brought to the hospital on recurrence or relapse.. A study of the population attending the 
Emergency Department may inform us regarding the % of them compared to those with 
acute psychosis.  The need for education regarding prophylactic treatment in 
schizophrenia has to be stressed. 
The high prevalence of medical co-morbidity known to be present in the schizophrenics 
was not found in the chart review of this population of patients. It may be due to the lack 
of reporting, recording, the medically ill dropping out unable to come for review due to 
disability  or due to financial overburden or death , or attending medical OPD with or 
without continuing the psychiatric medication.   
Substance use among this population was found to be less than that recorded for patients 
with  chronic schizophrenia as reported by Blanchard et al., (2000). Possible cause for this 
difference could be  the preponderance of women in this group of patients, under 
reporting, or the actual low prevalence in this group of subjects. 
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This graph summarizes the findings from the administration of the Schedule for 
Assessment of Insight – Expanded version (SAI -E) to this study population of patients 
with schizophrenia.  
The schedule for assessment of insight expanded version assesses mainly three 
dimensions of insight. The awareness of the patient about the changes in him or her, the 
attribution of these changes and the actions subsequent to it.  The first seven questions in 
the schedule assess the awareness, the next two questions the attribution and the last three 
the action. This graph shows the percentage of the scores the patients of this study 
population   scored in these different dimensions. In the dimension of awareness the 
patients of this study population scored 80% of the maximum score possible.  And the 
score in the dimension of attribution was 36 % of the maximum score possible, in this 
study population. In the dimension of action, the patients of this study population scored 
67 % of the maximum score.   
Though the majority of patients are having good insight, when the different dimensions of insight  
namely  awareness, attribution and action are concerned, it was seen that the scores were not uniform.  
Patients with mild or moderate severity only attend the regular outpatient department 
review.  Those on the extremes may not be getting regular treatment- neither prophylactic 
nor therapeutic. 
No patient scored as poor in insight as per the SAI E scale. It may be that only with good 
or moderate insight attend the outpatient reviews.   
Irrespective of gender 2/3 of the patients are non compliant as per Morisky scale. 
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Patients with mild or moderate severity only attend the regular outpatient department 
review.  Those on the extremes may not be getting regular treatment- neither prophylactic 
nor therapeutic. 
No patient scored as poor in insight as per the SAI E scale. It may be that only with good 
or moderate insight attend the outpatient reviews.   
 
Limitations 
Cross sectional design of the study. The cross sectional design of the study cannot reveal 
the change or the causes for change  in pattern of the different variables and the measured 
values over a period of time. The results cannot be extrapolated to the patient with acute 
onset schizophrenia who goes on to develop chronic schizophrenia.   
Sample bias. Sample bias related to the fact that this group of patients with schizophrenia 
belongs to a group of patients who attend a tertiary care hospital for treatment on a regular 
basis. Such a group is a priori compliant, regular for review and having less 
psychopathology and better insight- the same findings of the study.   
 
Clinical implications 
The study involved patients who come to the outpatient department  (OPD) accompanied 
by a carer who is usually a close family member. It may be that those who attend the  
OPD by proxy will give a different profile of demographic  and clinical features.  
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The severely ill and the well are less represented in this study population. It may be 
interpreted as the severely ill are either in the community and not reaching the treatment 
centres or that they  have become well either with treatment or with natural course.  
A follow up study of acute cases may give a better idea about the response to treatment, 
the different patterns of follow up and the reasons for the same.  
 
Future direction 
The follow up of the acute schizophrenia patients over a period of years may answer the 
few queries raised by this study.  Such studies may indicate the possible differences in the 
characteristics between the patients who attend the regular OPD and those who are lost for 
follow up. 
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CONCLUSIONS AND SUMMARY 
In this study population of patients with schizophrenia who regularly attend the outpatient 
department, the majority were females,  aged less than 35,  married, unemployed, 
belonging to  the low socio economic class, residing in the rural areas, Hindu by religion, 
having a  continuous course of disorder with mild severity,  manifesting  good insight,  
noncompliant with medication as per the Morisky scale  and compliant as per the chart 
review and  with no physical comorbidity or substance use or family history of any 
psychiatric morbidity. 
There was significant negative correlation between the total insight score as per SAI E 
and the total PANSS ( p value 0.007). Majority of patients (95 %) of this study population 
had a favourable attitude to medication. PANSS severity and Drug attitude inventory 
(DAI 10)   showed a negative association (p value =0.001) in that the more the 
psychopathology the less favourable was the attitude towards medication. According to 
the Morisky scale, the patients were less compliant regardless of the psychopathology as 
assessed by PANSS (0.046). As per the chart review however it was seen that patients 
with mild psychopathology were more compliant compared to those patients with 
moderate psychopathology.  (p=0.047). 
PANSS score was associated with insight, attitude to medication and compliance as 
assessed by the different tools. However insight was not related to compliance or attitude 
to medication.  
Though the assessment showed favourable attitude towards medication in the majority of 
patients with schizophrenia in this study population, it was not translated in to compliance 
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with medication.  Compliance with medication was seen associated with psychopathology 
but not with the other variables assessed in this study. Interventions targeted at improving 
compliance may have to be looked at for effective treatment of schizophrenia. Many of 
the queries may be clarified by the follow up studies of the acute schizophrenia patients 
who are brought to the OPD.  
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Appendix No.1 
Participant Information Sheet 
 
“Attitude to medication and insight in patients with schizophrenia” 
      My name is Dr. Subhalakshmi T.P. and I am doing a research on “Attitude to medication 
and insight in patients with schizophrenia”. The research will be done in  Department of 
psychiatry ,CMC,Vellore. 
 Patients’ insight in to their illness has been shown in some studies to affect their attitude to 
treatment and ultimately the outcome of the illness as well. 
         I am aiming to find out this relationship among the patients who attend the 
outpatient department here at the Mental Health centre for a study as part of my 
education.  I would like to request you to answer some questions related to your illness. I 
will also be collecting information regarding your illness from the case record kept in the 
hospital. 
   Your information will not be revealed to anyone and all information about you and your 
treatment will be kept confidential. This study is not likely to be of any direct benefit to 
you. 
     You have every right to refuse to take part in this study. Your treatment will not be 
affected by this. 
    If you have any doubts you can contact me at  04162284520 , department of psychiatry 
, CMC, Vellore. Email: subhalakshmitp@yahoo.com 
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Appendix No.3 
	  
CONSENT	  FORM	  
	   	  
In	  signing	  the	  document	  I	  am	  giving	  consent	  to	  be	  interviewed	  by	  Dr.	  T.	  P.	  Subhalakshmi,	  
post	  graduate	  student	  in	  Psychiatry	  at	  the	  Mental	  Health	  Centre,	  Bagayam.	  I	  understand	  that	  I	  
will	  be	  part	  of	  the	  research	  study	  on	  “Attitude	  to	  Medication	  and	  insight	  in	  patients	  with	  
schizophrenia”.	  	  
	   I	  further	  understand	  that	  I	  will	  be	  asked	  a	  few	  questions	  regarding	  my	  health	  status	  and	  
my	  responses	  to	  that	  will	  not	  affect	  my	  treatment	  or	  other	  related	  services.	  	  	  My	  participation	  
will	  be	  voluntary	  and	  granted	  freely.	  I	  also	  understand	  that	  I	  am	  free	  to	  	  revoke	  my	  permission	  at	  
any	  time	  during	  the	  study	  without	  affecting	  my	  treatment.	  	  	  	  
	   I	  am	  assured	  that	  the	  information	  that	  will	  be	  collected	  from	  me	  will	  be	  used	  only	  for	  this	  
study	  purpose	  and	  it	  will	  be	  kept	  confidential.	  	  
	   I	  am	  informed	  that	  the	  results	  of	  this	  research	  will	  be	  given	  to	  me	  if	  I	  ask	  for	  them.	  
	  
	  	  
Date	   	   	   	   	   	   	   	   Signature	  of	  the	  participant.	   	  
	   	   	   	   	   	   	   	   Name	  of	  the	  participant.	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